March 3, 2010 – Two poster sessions will highlight research of Atherotech’s VAP Cholesterol Test at the American College of Cardiology (ACC) Annual Scientific Session Exposition, March 14-16, in Atlanta.
The VAP (Vertical Auto Profile) Test, which identifies a far greater number of people at risk for heart disease than standard cholesterol tests, was utilized in Atherotech-sponsored research to be presented at the conference. This research is being presented at the sub-classes of lipoproteins session and the epidemiology session in hall B of the Georgia World Congress Center.
Poster presentation 1075-103 titled “Subfractions As Predictors of Angiographic Coronary Artery Disease Among Those With Normal and Abnormal LDL Levels” is being presented from 3:30-4:30 p.m. Sunday, March 14. Poster presentation 1128-96 “Apolipoprotein AI Predicts Future Death and Myocardial Infarction in Patients Undergoing Coronary Angiography Even When They Have Normal Baseline HDL Levels” is being presented from 9:30-10:30 a.m. Monday, March 15. Both presentations are moderated by Heidi T. May, Ph.D., MSPH, an epidemiologist at the Intermountain Medical Center in Murray, Utah.
Atherotech will also conduct blood draws to qualified attendees during regular exhibit hours. Because LDL is directly measured, fasting is not required. Test results will be returned to individuals via mail after the ACC conference. However, results for individuals tested Sunday will be available at the Atherotech booth Tuesday prior to the end of the conference.
The VAP Test reports 22 separate components of cholesterol and is covered by Medicare and most private insurance carriers. Unlike other lipid profiles, the VAP Test includes Lp(a) at no additional cost, and reports all three lipoprotein parameters — LDL, non-HDL and apoB — considered necessary by the expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology. The VAP Test also identifies markers of metabolic syndrome, which is frequently associated with early diabetes, and is the only single cholesterol test that routinely reports apoAI, apoB and the apoB/apoAI ratio.
Atherotech now provides physicians and cardiology practices with a single source for the VAP Cholesterol Test and more than a dozen cardiovascular and metabolic tests. Cardiometabolic testing available through Atherotech includes C-reactive protein (hsCRP), LpPLA2, ApoE genotype, NT-proBNP, cystatin-C, T3 and T4 when TSH is abnormal, plus gamma-glutamyl transferase (GGT), a recognized cardiovascular risk biomarker.
Atherotech’s booth is 1311.
For more information: www.thevaptest.com